Abcuro, Inc. is a clinical-stage biotechnology company based in Newton, Massachusetts, specializing in the development of breakthrough therapies for autoimmune diseases and cancer. With a focus on precise modulation of cytotoxic T and NK cells, Abcuro aims to target and treat these conditions through innovative approaches. Led by a team of experienced professionals and supported by a distinguished Board of Directors, the company is dedicated to advancing the field of immunotherapy and improving patient outcomes.
Abcuro's pipeline includes investigational monoclonal antibody ABC008, which selectively depletes highly cytotoxic T cells implicated in tissue damage in various autoimmune disorders. Additionally, the company is actively involved in clinical trials and research to explore the potential of their therapies in treating conditions such as Inclusion Body Myositis (IBM) and other indications. Committed to precision targeting and cutting-edge science, Abcuro is at the forefront of developing novel treatments that hold promise for patients suffering from autoimmune diseases and cancer.
Generated from the website